ASCO: Targeted RT Treats Certain Advanced Prostate Cancers

MONDAY, June 7, 2021 -- For previously treated metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA), 177Lu-PSMA-617 plus standard of care (SOC) improves radiographic progression-free...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news